WASHINGTON — When President Trump announced the administration’s deal to cut prices for weight-loss drugs, he proclaimed that “you will pay the lowest price anywhere in the world.” But state Medicaid programs might already be getting lower prices, according to a research firm.
Most-favored nation pricing is the main feature of the five deals that the administration has struck with Pfizer, AstraZeneca, EMD Serono, Novo Nordisk, and Eli Lilly. Companies have agreed to sell drugs to Medicaid at prices that are similar to what they charge other countries. Trump has consistently described the most-favored nation prices as the lowest price among comparable countries.
It’s not.
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply